Skip to main content
SpringerLink
Log in

Pharmacokinetic Optimisation in the Treatment of Pneumocystis carinii Pneumonia

  • Review Article
  • Pharmacokinetics-Therapeutics
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Several drugs and drug combinations are currently used in the treatment of patients with Pneumocystis carinii pneumonia (PCP) — pentamidine and cotrimoxazole (trimethoprim plus sulphamethoxazole), which are indicated for this usage, dapsone/trimethoprim and clindamycin/primaquine, which are not licensed for PCP, and trimetrexate/calcium folinate (leucovorin), eflornithine and BW-566C (566 C80) as investigational drugs. For most of these agents, recommendations regarding the use of pharmacokinetic parameters to establish individualised therapy cannot be made. The pharmacokinetics of antipneumocystis drugs are not well documented and clinical trials evaluating the relationship between the individual plasma pharmacokinetic profiles and responses to treatment are sparse.

In clinical trials, the reduction of the daily dose of pentamidine to 3 or 2 mg/kg/day and of cotrimoxazole to 15 mg/kg of the trimethoprim component resulted in a substantial reduction of frequency and severity of adverse drug effects without diminishing efficacy. For pentamidine, a long half-life of ⩾4 days implies the need for a loading dose. Plasma concentrations of the parent drug at steady-state varied between 30 and 100 µg/L. The elimination pharmacokinetics are characterised by several elimination slopes indicating the existence of a deep peripheral compartment. Due to its very low renal clearance, dosage adjustments are not necessary in patients with renal impairment.

The pharmacokinetics of cotrimoxazole follow first-order kinetics in PCP and the particular parameters are similar to those reported in the treatment of bacterial infection. Steady-state plasma concentrations of both trimethoprim and sulphamethoxazole are attained within 2 to 3 days, but the range of ‘therapeutic’ plasma concentrations must be newly defined, since elevated trimethoprim concentrations could not be correlated with the frequency and severity of adverse drug reactions. The concentrations of sulphamethoxazole may be at least as important as those of trimethoprim in defining a toxic range.

With dapsone/trimethoprim, clindamycin/primaquine and BW-566C (566 C 80) good clinical response rates were found in groups of patients with mild to moderate PCP. Comparative trials with standard drugs are still ongoing. Therapeutic to toxic concentration ratios have not been established in patients with PCP. Pharmacokinetic data pertaining to patients with PCP are either nonexistent or incomplete, or are complicated by a drug interaction between dapsone and trimethoprim suggesting an inhibition of metabolism of dapsone. Eflornithine and trimetrexate/calcium folinate have been used under specific research protocols, showing partial success as salvage agents for desperately ill patients with AIDS. Regarding all antipneumocystis drugs, additional clinical and pharmacokinetic data are needed to optimise and more fully individualise the treatment regimens for this severe infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Allegra CJ, Chabner BA, Tuazon CU, Ogata-Arakaki D, Baird B, et al. Trimetrexate for the treatment of pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 317: 978–985, 1987b

    Article  PubMed  CAS  Google Scholar 

  • Allegra CJ, Kovacs JA, Drake JC, Swan JC, Chabner BA, et al. Activity of antifolates against pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. Journal of Experimental Medicine 165: 926–931, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Armstrong D, Bernard E. Aerosol pentamidine. Annals of Internal Medicine 109: 852–854, 1988

    PubMed  CAS  Google Scholar 

  • Bell CA, Cory M, Fairley TA, Hall JE, Tidwell RR. Structure-activity relationships of pentamidine analogs against Giardia lamblia and correlation of antigiardial activity with DNA-binding affinity. Antimicrobial Agents and Chemotherapy 35: 1099–1107, 1991

    Article  PubMed  CAS  Google Scholar 

  • Bergan T, Örtengren B, Westerlund D. Clinical pharmacokinetics of co-trimazine. Clinical Pharmacokinetics 11: 372–386, 1986

    Article  PubMed  CAS  Google Scholar 

  • Berger BJ, Naiman NA, Hall JE, Peggins J, Brewer TG, et al. Primary and secondary metabolism of pentamidine by rats. Antimicrobial Agents and Chemotherapy 36: 1825–1831, 1992

    Article  PubMed  CAS  Google Scholar 

  • Berger BJ, Reddy VV, Le ST, Lombardy RJ, Hall JE, et al. Hydroxylation of pentamidine by rat liver microsomes. Journal of Pharmacology and Experimental Therapeutics 256: 883–889, 1991

    PubMed  CAS  Google Scholar 

  • Berman JD, Fleckenstein L. Pharmacokinetic justification of antiprotozoal therapy. Clinical Pharmacokinetics 21: 479–493, 1991

    Article  PubMed  CAS  Google Scholar 

  • Bernard EM, Sepkowitz KA, Telzak EE, Armstrong D. Pneumocystosis. Medical Clinics of North America 76: 107–119, 1992

    PubMed  CAS  Google Scholar 

  • Black JR, Feinberg J, Murphy RL, Fass RJ, Carey J, et al. Clindamycin and primaquine as primary treatment for mild and moderately severe pneumocystis carinii pneumonia in patients with AIDS. European Journal of Clinical Microbiology and Infectious Diseases 10: 204–207, 1991

    Article  CAS  Google Scholar 

  • Böhni E. Vergleichende bakteriologische Untersuchungen mit der Kombination Trimethoprim/Sulfamethoxazol in vitro and in vivo. Chemotherapy 14 (Suppl.): 1–21, 1969

    PubMed  Google Scholar 

  • Bouchard Ph, Sai P, Reach G, Caubarrère I, Ganeval D, et al. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes 31: 40–45, 1982

    Article  PubMed  CAS  Google Scholar 

  • Bowden FJ, Harman PJ, Lucas CR. Serum trimethoprim and sulphamethoxazole levels in AIDS. Lancet 1: 853, 1986

    Article  PubMed  CAS  Google Scholar 

  • Bozzette SA, Sattler FR, Chiu J, Wu AW, Gluckstein D, et al. A controlled trial of early adjunctive treatment with corticosteroids for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. New England Journal of Medicine 323: 1451–1457, 1990

    Article  PubMed  CAS  Google Scholar 

  • Broughton MC, Queener SF. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. Antimicrobial Agents and Chemotherapy 35: 1348–1355, 1991

    Article  PubMed  CAS  Google Scholar 

  • Bryceson A. Pentamidine: which salt? Lancet 1: 1395, 1988

    Google Scholar 

  • Coleman MD, Scott AK, Breckenridge AM, Park BK. The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man. British Journal of Clinical Pharmacology 30: 761–767, 1990

    Article  PubMed  CAS  Google Scholar 

  • Comtois R, Pouliot J, Vinet B, Gervais A, Lemieux C. Higher pentamidine levels in AIDS patients with hypoglycemia and azotemia during treatment of Pneumocystis carinii pneumonia. Americal Review of Respiratory Diseases 146: 740–744, 1992

    CAS  Google Scholar 

  • Conte JE. Pharmacokinetics of intravenous pentamidine in patients with normal function or receiving hemodialysis. Journal of Infectious Diseases 163: 169–175, 1991

    Article  PubMed  Google Scholar 

  • Conte JE, Chernoff D, Feigal DW, Joseph P, McDonald CH, et al. Intravenous or inhaled pentamidine for treating pneumocystis carinii pneumonia in AIDS. Annals of Internal Medicine 113: 203–209, 1990

    PubMed  Google Scholar 

  • Conte JE, Upton RA, Lin ET. Pentamidine pharmacokinetics in patients with AIDS with impaired renal function. Journal of Infectious Diseases 156: 885–890, 1987

    Article  PubMed  Google Scholar 

  • Cushion MT, Stanforth D, Linke MJ, Walzer PD. Method of testing the susceptibility of pneumocystis carinii to antimicrobial agents in vitro. Antimicrobial Agents and Chemotherapy 28: 796–801, 1985

    Article  PubMed  CAS  Google Scholar 

  • Debs RJ, Straubinger RM, Brunette EN, Lin JM, Lin EJ, et al. Selective enhancement of pentamidine uptake in the lung by aerosolization and delivery in liposomes. American Review of Respiratory Diseases 135: 731–737, 1987

    CAS  Google Scholar 

  • DeGowin RL, Eppes B, Powell RD, Carson PE. The haemolytic effects of diphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bulletin of the World Health Organisation 35: 165–179, 1966

    CAS  Google Scholar 

  • Donnelly H, Bernard EM, Rothkotter H, Gold JWM, Armstrong D. Distribution of pentamidine in patients with AIDS. Journal of Infectious Diseases 157: 985–989, 1988

    Article  PubMed  CAS  Google Scholar 

  • Drake S, Lampasona V, Nicks HL, Schwarzmann SW. Pentamidine isethionate in the treatment of pneumocystis carinii pneumonia. Clinical Pharmacy 4: 507–516, 1985

    PubMed  CAS  Google Scholar 

  • Drug Information for the Health Care Professional. USP DI, 8th ed., Vol. 1B, United States Pharmacopeial Convention Inc. 1717, Rockville, 1988

  • Dusci LJ, Hackett LP, Forbes AM, Ilett KF. High-performance liquid Chromatographic method for measurements of pentamidine in plasma and its application in an immunosuppressed patient with renal dysfunction. Therapeutic Drug Monitoring 9: 422–425, 1987

    Article  PubMed  CAS  Google Scholar 

  • Editorial. Pentamidine methanesulfonate to be distributed by CDC. Morbidity and Mortality Weekly Report 33: 226–227, 1984

  • Edstein MD, Rieckmann KH, Veenendaal JR. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim®) in man. British Journal of Clinical Pharmacology 30: 259–265, 1990

    Article  PubMed  CAS  Google Scholar 

  • Eeftinck Schattenkerk JKM, Lange JMA, van Steenwijk RP, Danner SA. Can the course of high dose cotrimoxazole for pneumocystis carinii pneumonia in AIDS be shorter? A possible solution to the problem of cotrimoxazole toxicity. Journal of Internal Medicine 227: 359–362, 1990

    Article  PubMed  CAS  Google Scholar 

  • Falloon J, Kovacs J, Hughes W, O’Neill D, Polis M, et al. A preliminary evaluation of 566C80 for the treatment of pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 325: 1534–1538, 1991

    Article  PubMed  CAS  Google Scholar 

  • Falloon J, Lavelle J, Ownby K, O’Leary C, Noblin J, et al. Pharmacokinetics of oral 566C80 in AIDS. VIII International Conference on AIDS/III STD World Congress, Amsterdam. Abstract no. PoB 3296, 1992

  • Feddersen A, Sack K. Experimental studies on the nephrotoxicity of pentamidine in rats. Journal of Antimicrobial Chemotherapy 28: 437–446, 1991

    Article  PubMed  CAS  Google Scholar 

  • Feinberg J, McDermott C, Nutter J. Trimctrexatc (TMTX) salvage therapy for PCP in AIDS patients with limited therapeutic options. VIII International Conference on AIDS/III STD World Congress, Amsterdam. Abstract no. PoB 3297. 1992

  • Fitzsimmons WE, Luskin SS. Pentamidine therapy in renal failure: case report and literature review. Drug Intelligence and Clinical Pharmacy 22: 25–28, 1988

    PubMed  CAS  Google Scholar 

  • Fletcher KA, Price Evans DA, Gilles HM, Greaves J, Bunnag D, et al. Studies on the pharmacokinetics of primaquine. Bulletin of the World Health Organization 59: 407–412, 1981

    PubMed  CAS  Google Scholar 

  • Freedberg KA, Tosteson ANA, Cohen CJ, Cotton DJ. Primary prophylaxis for pneumocystis carinii pneumonia in HIV-in-fected people with CD4 counts below 200/mm3: a cost-effectiveness analysis. Journal of Acquired Immune Deficiency Syndromes 4: 521–531, 1991

    PubMed  CAS  Google Scholar 

  • Gagnon S, Boota AM, Fischl MA, Baier H, Kirsey OW, et al. Corticosteroids as adjunctive therapy for severe pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a double-blind, placebo-controlled trial. New England Journal of Medicine 323: 1444–1450, 1990

    Article  PubMed  CAS  Google Scholar 

  • Gatti G, Flaherty J, Borin M, Gambertoglio J. Comparative study of clindamycin bioavailability and pharmacokinetics in AIDS patients. VIII International Conference on AIDS/III STD World Congress, Amsterdam. Abstract no. PoB 3176, 1992

  • Gibaldi M, Perrier D. Pharmacokinetics, Marcel Dekker Inc., New York, 1975

    Google Scholar 

  • Gilman TM, Paulson YJ, Cohen JL, Heseltine PNR, Boylen CT. Multiple-dose pharmacokinetics of eflornithine in AIDS patients treated for pneumocystis carinii pneumonia. 3rd International Conference on AIDS, Washington. Abstract no. THP.151, 1987

  • Gilman TM, Paulson YJ, Cohen JL, Heseltine PNR, Boylen CT. Multiple-dose pharmacokinetics of eflornithine in AIDS patients treated for pneumocystis carinii pneumonia. 9th Annual Meeting of the American College of Clinical Pharmacy, Philadelphia. Abstract no. 51 E, 1988

  • Gleckman R, Alvarez S, Joubert DW. Drug reviews: trimethoprim-sulfamethoxazole. American Journal of Hospital Pharmacy 36: 893–906, 1979

    PubMed  CAS  Google Scholar 

  • Goa KL, Campoli-Richards DM. Pentamidine isethionate: a review of its antiprotozoal activity, pharmacokinetic properties and therapeutic use in pneumocystis carinii pneumonia. Drugs 33: 242–258, 1987

    Article  PubMed  CAS  Google Scholar 

  • González-Ruiz A, Haworth SJ, O’Neil AB, Warhurst DC. Dapsone in low doses prevents pneumocystis carinii pneumonia in the rat model. Journal of Infection 22: 143–152, 1991

    Article  PubMed  Google Scholar 

  • Goodman AG, Rall TW, Nies AS, Taylor P (Eds). The pharmacological basis of therapeutics, 8th ed., pp. 988–991, Pergamon Press, New York, 1990

    Google Scholar 

  • Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 100: 495–499, 1984

    PubMed  CAS  Google Scholar 

  • Grose WE, Bodey GP, Loo TL. Clinical pharmacology of intravenously administered trimethoprim-sulfamethoxazole. Antimicrobial Agents and Chemotherapy 15: 447–451, 1979

    Article  PubMed  CAS  Google Scholar 

  • Grossman SJ, Jollow DJ. Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia. Journal of Pharmacology and Experimental Therapeutics 244: 118–125, 1988

    PubMed  CAS  Google Scholar 

  • Hansen IB. The combination trimethoprim-sulfamethoxazole. In Schönfeld H (Ed) Antibiotics and chemotherapy, volume 25, pp. 217–232, Karger, Basel, 1978

    Google Scholar 

  • Haverkos HW. Assessment of therapy for pneumocystis carinii pneumonia. American Journal of Medicine 76: 501–508, 1984

    Article  PubMed  CAS  Google Scholar 

  • Ho DHW, Covington WP, Legha SS, Newman RA, Krakoff IH. Clinical pharmacology of trimetrexate. Clinical Pharmacology and Therapeutics 42: 351–356, 1987

    Article  PubMed  CAS  Google Scholar 

  • Hughes WT. A new drug (566C80) for the treatment of pneumocystis carinii pneumonia. Annals of Internal Medicine 116: 953–954, 1992

    PubMed  CAS  Google Scholar 

  • Hughes WT, Feldman S, Chaudhary SC, Ossi MJ, Cox F, et al. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of pneumocystis carinii pneumonia. Journal of Pediatrics 92: 285–291, 1978

    Article  PubMed  CAS  Google Scholar 

  • Hughes WT, Feldman S, Sanyal SK. Treatment of pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole. Canadian Medical Association Journal 112 (Suppl.): 47S–50S, 1975

    Google Scholar 

  • Hughes WT, Gray VL, Gutteridge WE, Latter VS, Pudney M. Efficacy of a hydroxynaphthoquinone, 566 C 80, in experimental Pneumocystis carinii pneumonitis. Antimicrobial Agents and Chemotherapy 34: 225–228, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hughes WT, Kennedy W, Shenep JL, Flynn PM, Hetherington SV, et al. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-pneumocystis carinii activity: a phase I study in human immunodeficiency (HIV)-infected men. Journal of Infectious Diseases 163: 843–848, 1991

    Article  PubMed  CAS  Google Scholar 

  • Hughes WT, Leoung G, Kramer F, Bozzette S, Frame P, et al. Comparison of 566C80 and trimethoprim-sulfamethoxazole (TMP-SMZ) for the treatment of P. carinii pneumonitis (PCP). VIII International Conference on AIDS/III STD World Congress, Amsterdam. Abstract no. WeB 1019, 1992

  • Hughes WT, Price RA, Kim HK, Coburn TP, Grigsby D, et al. Pneumocystis carinii pneumonitis in children with malignancies. Journal of Pediatrics 82: 404–415, 1973

    Article  PubMed  CAS  Google Scholar 

  • Hughes WT, Smith BL. Efficacy of diaminodiphenylsulfone and other drugs in murine pneumocystis carinii pneumonitis. Antimicrobial Agents and Chemotherapy 26: 436–440, 1984

    Article  PubMed  CAS  Google Scholar 

  • Ivády G, Páldy L. Ein neues Behandlungsverfahren der interstitiellen plasmazelligen Pneumonie Frühgeborener mit fünfwertigem Stibium und aromatischen Diamidinen. Monatsschrift für Kinderheilkunde 106: 10–14, 1957

    Google Scholar 

  • Ivády G, Páldy L, Unger G. Weitere Erfahrungen bei der Behandlung der interstitiellen plasmacellulären Pneumonie mit Pentamidin. Monatsschrift für Kinderheilkunde 111: 297–299, 1963

    PubMed  Google Scholar 

  • Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Reviews of Infectious Diseases 4: 426–428, 1982

    Article  PubMed  CAS  Google Scholar 

  • Jones SK, Hall JE, Allen MA, Morrison SD, Ohemeng KA, et al. Novel pentamidine analogs in the treatment of experimental pneumocystis carinii pneumonia. Antimicrobial Agents and Chemotherapy 34: 1026–1030, 1990

    Article  PubMed  CAS  Google Scholar 

  • Kay R, Dubois RE. Clindamycin/primaquine therapy and secondary prophylaxis against pneumocystis carinii pneumonia in patients with AIDS. Southern Medical Journal 83: 403–404, 1990

    Article  PubMed  CAS  Google Scholar 

  • Kennedy E, Frischer H. Distribution of primaquine in human blood: drug-binding to α1-glycoprotein. Journal of Laboratory and Clinical Medicine 116: 871–878, 1990

    PubMed  CAS  Google Scholar 

  • Klein NC, Duncanson FP, Lenox TH, Forszpaniak C, Sherer CB, et al. Trimethoprim-sulfamethoxazole versus pentamidine for pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS 6: 301–315, 1992

    Article  PubMed  CAS  Google Scholar 

  • Kovacs JA, Allegra J, Beaver J, Boarman D, Lewis M, et al. Characterization of de novo folate synthesis in pneumocystis carinii and toxoplasma gondii: potential for screening therapeutic agents. Journal of Infectious Diseases 160: 312–320, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Annals of Internal Medicine 100: 663–671, 1984

    PubMed  CAS  Google Scholar 

  • Kovacs JA, Masur H. Pneumocystis carinii pneumonia: therapy and prophylaxis. Journal of Infectious Diseases 158: 254–259, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kovacs JA, Masur H. Are corticosteroids beneficial as adjunctive therapy for pneumocystis pneumonia in AIDS? Annals of Interna! Medicine 113: 1–3, 1990

    CAS  Google Scholar 

  • Lau WK, Young LS. Trimethoprim-sulfamethoxazole treatment of pneumocystis carinii pneumonia in adults. New England Journal of Medicine 295: 716–718, 1976

    Article  PubMed  CAS  Google Scholar 

  • Lee BL, Medina I, Benowitz NL, Jacob P, Wofsy CB, et al. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Annals of Internal Medicine 110: 606–611, 1989

    PubMed  CAS  Google Scholar 

  • Leoung GS, Mills J, Hopewell PC, Hughes W, Wofsy C. Dapsonetrimethoprim for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Annals of Internal Medicine 105: 45–48, 1986

    PubMed  CAS  Google Scholar 

  • Lidman C, Örtqvist Å, Lundbergh P, Julander I, Bergdahl S. Pneumocystis carinii pneumonia in Stockholm, Sweden: treatment, outcome, one-year follow-up and pyrimethamine prophylaxis. Scandinavian Journal of Infectious Diseases 21: 381–387, 1989

    Article  PubMed  CAS  Google Scholar 

  • Lin JT, Cashmore AR, Baker M, Dreyer RN, Ernstoff M, et al. Phase I studies with trimetrexate: clinical pharmacology, analytical methodology, and pharmacokinetics. Cancer Research 47: 609–616, 1987

    PubMed  CAS  Google Scholar 

  • Luce JM, Hopewell PC. Aerosolized pentamidine for Pneumocystis carinii pneumonia. Chest 96: 713–714, 1989

    Article  PubMed  CAS  Google Scholar 

  • Makulu DR, Waalkes TP. Interaction between aromatic diamines and nucleic acids: possible implications for chemotherapy. Journal of the National Cancer Institute 54: 305–309, 1975

    PubMed  CAS  Google Scholar 

  • Mashford L, Lucas CR, Stewart K, Bowden FJ. Serum levels of trimethoprim and sulfamethoxazole following a lower dose of co-trimoxazole in the treatment of pneumocystis carinii pneumonia. 7th International Conference on AIDS, Florence. Abstract no. W.B.2183, 1991

  • May DG, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clinical Pharmacology and Therapeutics 48: 619–627, 1990

    Article  PubMed  CAS  Google Scholar 

  • Medina I, Mills J, Leoung G, Hopewell PC, Lee B, et al. Oral therapy for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. New England Journal of Medicine 323: 776–782, 1990

    Article  PubMed  CAS  Google Scholar 

  • Mihaly GW, Ward SA, Edwards G, L’Eorme M, Breckenridge AM. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. British Journal of Clinical Pharmacology 17: 441–446, 1984

    Article  PubMed  CAS  Google Scholar 

  • Mills J, Leoung G, Medina I, Hopewell PC, Hughes WT, et al. Dapsone treatment of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Antimicrobial Agents and Chemotherapy 32: 1057–1060, 1988

    Article  PubMed  CAS  Google Scholar 

  • Montaner JSG, Lawson LM, Levitt N, Belzberg A, Schechter MT, et al. Corticosteroids prevent early deterioration in patients with moderately severe pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 113: 14–20, 1990

    PubMed  CAS  Google Scholar 

  • Montgomery AB, Debs RJ, Luce JM, Corkery KJ, Turner J, et al. Aerosolised pentamidine as sole therapy for pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet 2: 480–483, 1987

    Article  PubMed  CAS  Google Scholar 

  • Montgomery AB, Debs RJ, Luce JM, Corkery KJ, Turner J, et al. Selective delivery of pentamidine to the lung by aerosol. American Review of Respiratory Diseases 137: 477–478, 1988

    CAS  Google Scholar 

  • Montgomery AB, Edison RE, Sattler F, Hopewell P, Mason G, et al. Aerosolized pentamidine vs. trimethoprim/sulfamethoxazole for acute pneumocystis carinii pneumonia (PCP): a randomized double blind trial. 6th International Conference on AIDS, San Francisco. Abstract no. Th.B.395, 1990

  • Murray JF, Felton CP, Garay SM, Gottlieb MS, Hopewell PC, et al. Pulmonary complications of the acquired immunodeficiency syndrome. New England Journal of Medicine 310: 1682–1688, 1984

    Article  PubMed  CAS  Google Scholar 

  • Navin TR, Dickinson CM, Adams SR, Mayersohn M, Juranek DD. Effect of azotemia in dogs on the pharmacokinetics of pentamidine. Journal of Infectious Diseases 155: 1020–1026, 1987

    Article  PubMed  CAS  Google Scholar 

  • O’Doherty M, Thomas S, Page Ch, Bradbeer C, Nunan T, et al. Pulmonary deposition of nebulised pentamidine isethionate: effect of nebuliser type, dose, and volume of fill. Thorax 45: 460–464, 1990

    Article  PubMed  Google Scholar 

  • Panisko DM, Keystone JS. Treatment of malaria — 1990. Drugs 39: 160–189, 1990

    Article  PubMed  CAS  Google Scholar 

  • Patel RB, Welling PG. Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole). Clinical Pharmacokinetics 5: 405–423, 1980

    Article  PubMed  CAS  Google Scholar 

  • Peters JH, Murray JF, Gordon GR, Gelber RH. Dapsone in saliva and plasma of man. Pharmacology 22: 162–171, 1981

    Article  PubMed  CAS  Google Scholar 

  • Plaisance KI, Drusano GL, Forrest A, Townsend RI, Standiford HC. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrobial Agents and Chemotherapy 33: 618–620, 1989

    Article  PubMed  CAS  Google Scholar 

  • Queener SF, Bartlett MS, Richardson JD, Durkin MM, Jay MA, et al. Activity of clindamycin with primaquine against pneumocystis carinii in vitro and vivo. Antimicrobial Agents and Chemotherapy 32: 807–813, 1988

    Article  PubMed  CAS  Google Scholar 

  • Rogers P, Allegra CJ, Murphy RF, Drake JC, Masur H, et al. Bioavailability of oral trimetrexate in patients with acquired immunodeficiency syndrome. Antimicrobial Agents and Chemotherapy 32: 324–326, 1988

    Article  PubMed  CAS  Google Scholar 

  • Ruf B, Rohde I, Pohle HD. Efficacy of clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment of pneumocystis carinii pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 10: 207–210, 1991

    Article  CAS  Google Scholar 

  • Sahai J, Berry AJ. Eflornithine for the treatment of pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review. Pharmacotherapy 9: 29–33, 1989

    PubMed  CAS  Google Scholar 

  • Saimot AG, Girard PM. Pneumopathie à pneumocystis carinii au cours de l’infection à VIH. Presse Médicale 16: 258–264, 1991

    Google Scholar 

  • Salamone FR, Cunha BA. Update of pentamidine for the treatment of pneumocystis carinii pneumonia. Clinical Pharmacy 7: 501–510, 1988

    PubMed  CAS  Google Scholar 

  • Sands M, Kron MA, Brown RB. Pentamidine: a review. Reviews of Infectious Diseases 7: 625–634, 1985

    Article  PubMed  CAS  Google Scholar 

  • Sattler FR, Allegra CJ, Verdegem TD, Akil B, Tuazon CU, et al. Trimetrexate-leucovorin dosage evaluation study for treatment of pneumocystis carinii pneumonia. Journal of Infectious Diseases 161: 91–96, 1990

    Article  PubMed  CAS  Google Scholar 

  • Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Annals of Internal Medicine 109: 280–287, 1988

    PubMed  CAS  Google Scholar 

  • Sattler FR, Feinberg J. New developments in the treatment of pneumocystis carinii pneumonia. Chest 101: 451–457, 1992

    Article  PubMed  CAS  Google Scholar 

  • Schoenbach EB, Greenspan EM. The pharmacology, mode of action and therapeutic potentialities of stilbamidine, propamidine and other aromatic diamidines — a review. Medicine 27: 327–377, 1948

    Article  PubMed  CAS  Google Scholar 

  • Shelhamer JH, Ognibene FP, Macher AM, Tuazon C, Steiss R, et al. Persistence of pneumocystis carinii in lung tissue of acquired immunodeficiency syndrome patients treated for pneumocystis pneumonia. American Review of Respiratory Diseases 130: 1161–1165, 1984

    CAS  Google Scholar 

  • Siber GR, Gorham CC, Ericson JF, Smith AL. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Reviews of Infectious Diseases 4: 566–578, 1982

    Article  PubMed  CAS  Google Scholar 

  • Siegel SE, Wolff LJ, Baehner RL, Hammond D. Treatment of pneumocystis carinii pneumonitis. American Journal of Diseases of Children 138: 1051–1054, 1984

    PubMed  CAS  Google Scholar 

  • Sjoerdsma A, Schechter PJ. Chemotherapeutic implications of polyamine biosynthesis inhibition. Clinical Pharmacology and Therapeutics 35: 287–300, 1984

    Article  PubMed  CAS  Google Scholar 

  • Smaldone GC, Fuhrer J, Steigbigel RT, McPcck M. Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infections. American Review of Respiratory Diseases 143: 727–737, 1991

    CAS  Google Scholar 

  • Small CB, Harris CA, Friedland GH, Klein RS. The treatment of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Archives of Internal Medicine 145: 837–840, 1985

    Article  PubMed  CAS  Google Scholar 

  • Smith D, Davies S, Nelson M, Youle M. Gleeson J, et al. Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy. AIDS 4: 1019–1021, 1990

    Article  PubMed  CAS  Google Scholar 

  • Smith DE, Davies S, Smithson J, Harding I, Gazzard BG. Eflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients. AIDS 6: 1489–1493, 1992

    Article  PubMed  CAS  Google Scholar 

  • SooHoo GW, Mohsenifar Z, Meyer RD. Inhaled or intravenous pentamidine therapy for pneumocystis carinii pneumonia in AIDS. Annals of Internal Medicine 113: 195–202, 1990

    CAS  Google Scholar 

  • Stehr-Green JK, Helmick CG. Pentamidine and renal toxicity. New England Journal of Medicine 313: 694–695, 1985

    PubMed  CAS  Google Scholar 

  • Tidwell RR, Jones SK, Geratz JD, Ohemeng KA, Bell CA, et al. Development of pentamidine analogues as new agents for the treatment of pneumocystis carinii pneumonia. Annals of the New York Academy of Sciences 616: 421–441, 1990a

    Article  PubMed  CAS  Google Scholar 

  • Tidwell RR, Jones SK, Geratz JD, Ohemeng KA, Cory M, Hall JE. Analogues of l,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental pneumocystis carinii pneumonia. Journal of Medicinal Chemistry 33: 1252–1257, 1990b

    Article  PubMed  CAS  Google Scholar 

  • Tidwell RR, Kilgore SG, Ohemeng KA, Geratz JD, Hall JE. Treatment of experimental pneumocystis carinii pneumonia with analogs of pentamidine. Journal of Protozoology 36: 74S–76S, 1989

    PubMed  CAS  Google Scholar 

  • Toma E. Clindamycin/primaquine for treatment of pneumocystis carinii pneumonia in AIDS. European Journal of Clinical Microbiology and Infectious Diseases 10: 210–213, 1991

    Article  CAS  Google Scholar 

  • Toma E, Fournier S, Dumont M, Bolduc P, Deschamps H. Clindamycin/primaquine versus trimethoprim/sulfamethoxazole as primary therapy for pneumocystis carinii pneumonia in AIDS. VIII International Conference on AIDS/III STD World Congress, Amsterdam. Abstract no. WeB 1020, 1992

  • Townsend RJ, Baker RP. Pharmacokinetic comparison of three clindamycin phosphate dosing schedules. Drug Intelligence and Clinical Pharmacy 21: 279–281, 1987

    PubMed  CAS  Google Scholar 

  • Vöhringer HF, Arastéh K. Pharmakokinetik von Pentamidin bei knochenmarktransplantierten und AIDS-patienten. In Link et al. (Eds) Pneumocystis-carinii-Pneumonie bei Immunsuppression, pp. 25–32, Walter de Gruyter, Berlin, New York, 1991

    Google Scholar 

  • Vöhringer HF, Arastéh K, Link H, Ehninger G, Hardtmann I. Determinanten der Pentamidin-konzentration im Serum beim Menschen. Medizinische Klinik 87 (Suppl. I): 24–29, 1992b

    PubMed  Google Scholar 

  • Vöhringer HF, Arastéh K, Stratmann M. Influence of different dosages on pharmacokinetics and pharmacodynamics of pentamidine in HIV patients. Klinische Pharmakologie Aktuell 3: 38–39, 1992a

    Google Scholar 

  • Walzer PD, Kim CK, Foy J, Linke MJ, Cushion MT. Cationic anti-trypanosomal and other antimicrobial agents in the therapy of experimental pneumocystis carinii pneumonia. Antimicrobial Agents and Chemotherapy 32: 896–905, 1988

    Article  PubMed  CAS  Google Scholar 

  • Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States. Annals of Internal Medicine 80: 83–93, 1974

    PubMed  CAS  Google Scholar 

  • Ward SA, Mihaly GW, Edwards G, Looareesuwan S, Phillips RE, et al. Pharmacokinetics of primaquine in man II: comparison of acute vs chronic dosage in Thai subjects. British Journal of Clinical Pharmacology 19: 751–755, 1985

    Article  PubMed  CAS  Google Scholar 

  • Waskin H, Stehr-Green JK, Heimick CG, Sattler FR. Risk factors for hypoglycemia associated with pentamidine therapy for pneumocystis pneumonia. Journal of the American Medical Association 260: 345–347, 1988

    Article  PubMed  CAS  Google Scholar 

  • Western KA, Norman L, Kaufman AF. Failure of pentamidine isethionate to provide chemoprophylaxis against pneumocystis carinii infection in rats. Journal of Infectious Diseases 131: 273–276, 1975

    Article  PubMed  CAS  Google Scholar 

  • Western KA, Perera DR, Schultz MG. Pentamidine isethionate in the treatment of pneumocystis carinii pneumonia. Annals of Internal Medicine 73: 695–702, 1970

    PubMed  CAS  Google Scholar 

  • Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld W, et al. Trimethoprim-sulfamethoxazole or pentamidine for pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Annals of Internal Medicine 105: 37–44, 1986

    PubMed  CAS  Google Scholar 

  • Williamson J. Effects of trypanocides on the fine structure of target organism. Pharmacology and Therapeutics 7: 445–512, 1979

    Article  PubMed  CAS  Google Scholar 

  • Winston DJ, Lau WK, Gale RP, Young LS. Trimethoprim-sulfamethoxazole for the treatment of pneumocystis carinii pneumonia. Annals of Internal Medicine 92: 762–769, 1980

    PubMed  CAS  Google Scholar 

  • Wöber A, Langmann P, Ernemann U, Warzecha KD, Joeres R, et al. Trimethoprim/sulfamethoxazole therapy in patients with AIDS-associated pneumocystis pneumonia — plasma concentrations — adverse effects. AIDS-Forschung (AIFO) 9: 475–481, 1990

    Google Scholar 

  • Wofsy CB. Treatment and prevention of pneumocystosis in AIDS. In Lode & Höffken (Eds) AIDS and lung, pp. 74–87, Georg Thieme Verlag, Stuttgart-New York, 1991

    Google Scholar 

  • Wordell CJ, Hauptman SP. Treatment of pneumocystis carinii pneumonia in patients with AIDS. Clinical Pharmacy 7: 514–527, 1988

    PubMed  CAS  Google Scholar 

  • Young LS. Trimethoprim-sulfamethoxazole in the treatment of adults with pneumonia due to pneumocystis carinii. Reviews of Infectious Diseases 4: 608–613, 1982

    Article  PubMed  CAS  Google Scholar 

  • Zambrano D. Clindamycin in the treatment of obstetric and gynecologic infections: a review. Clinical Therapeutics 13: 58–80, 1991

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Auguste-Viktoria-Krankenhaus, Akademisches Lehrkrankenhaus der Freien Universität Berlin, Berlin, Federal Republic of Germany

    Hans-Friedrich Vöhringer & Keikawus Arastéh

Authors
  1. Hans-Friedrich Vöhringer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keikawus Arastéh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vöhringer, HF., Arastéh, K. Pharmacokinetic Optimisation in the Treatment of Pneumocystis carinii Pneumonia. Clin. Pharmacokinet. 24, 388–412 (1993). https://doi.org/10.2165/00003088-199324050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199324050-00004

Keywords

Search

Navigation